SpringWorks Therapeutics (NASDAQ:SWTX – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.04, Briefing.com reports. The business had revenue of $49.10 million during the quarter, compared to analysts’ expectations of $53.28 million. During the same period in the previous year, the company posted ($1.27) earnings per share. SpringWorks Therapeutics’s revenue for the quarter was up 4810.0% compared to the same quarter last year.
SpringWorks Therapeutics Stock Down 1.3 %
SWTX stock opened at $33.10 on Wednesday. The company’s 50-day simple moving average is $32.95 and its 200-day simple moving average is $37.23. SpringWorks Therapeutics has a 52-week low of $18.00 and a 52-week high of $53.92. The firm has a market cap of $2.46 billion, a P/E ratio of -7.47 and a beta of 0.79.
Wall Street Analyst Weigh In
Several equities research analysts have commented on the stock. Wedbush reaffirmed an “outperform” rating and issued a $77.00 price target on shares of SpringWorks Therapeutics in a report on Thursday, November 7th. HC Wainwright lowered their price target on shares of SpringWorks Therapeutics from $76.00 to $74.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, JPMorgan Chase & Co. upped their price target on shares of SpringWorks Therapeutics from $64.00 to $68.00 and gave the company an “overweight” rating in a report on Wednesday, September 4th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, SpringWorks Therapeutics has a consensus rating of “Buy” and a consensus price target of $68.17.
About SpringWorks Therapeutics
SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.
See Also
- Five stocks we like better than SpringWorks Therapeutics
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Is Palantir’s AI Edge Enough to Justify Its Price?
- What is Put Option Volume?
- 3 Stocks With Special Dividends: Big Payouts for Savvy Investors
Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
